This guide provides details of the GST treatment applicable to the biomedical
industry.
The biomedical industry is a key growth engine of Singapore’s economy and
one of the fastest growing sectors. To facilitate growth, IRAS collaborated with
the GST Services of the Big 4 CPA Firms to co-design GST solutions to
address various issues faced by the industry.
Specifically, to enhance the international competitiveness of our local industry,
business-friendly GST measures have been introduced to relieve the
irrecoverable GST costs incurred by businesses as well as to facilitate GST
compliance along the supply chain. The measures are explained in
paragraphs 3 and 4 below.
This guide also clarifies the GST treatment for other common scenarios and
issues in the biomedical industry
Source: gov.sg
Latest Posts in "Singapore"
- Singapore Mandates InvoiceNow E-Invoicing for All New GST Registrants from April 2028
- Singapore Mandates GST E-Invoicing for All Businesses by 2031, Phased Rollout Starts 2028
- Singapore Mandates InvoiceNow E-Invoicing for All GST-Registered Businesses by 2031
- Singapore Expands E-Invoicing Mandate: New Compliance Deadlines for All GST-Registered Businesses
- Singapore IRAS Announces Phased Peppol E-Invoice Reporting Rollout from 2028 to 2031














